Growth hormone-releasing peptides (GHRPs)

FDA status (April 2026): GHRPs (GHRP-6, GHRP-2, hexarelin) are not FDA-approved for any therapeutic indication. These compounds are classified under FDA compounding regulations and are listed on the WADA prohibited substances list. Access requires a licensed prescriber and an accredited compounding pharmacy. Regulatory status may change. Verify current rules before pursuing therapy.

Growth hormone-releasing peptides (GHRPs) are synthetic peptides that stimulate pituitary GH secretion. They also exert direct, GH-independent cytoprotective effects through two distinct receptors: GHS-R1a and CD36.

Endocrinologist Cyril Bowers first described GHRP-6 in the early 1980s. It was the founding member of the class. GHRP-6 triggers dose-related GH release both in vitro and in vivo. Unlike exogenous GH injections, GHRPs activate multiple protective pathways at once. They stimulate PI-3K/AKT1 pro-survival signaling, reduce reactive oxygen species (ROS), inhibit NF-kB-driven inflammation, and suppress fibrogenic cytokines (TGF-B1, CTGF).

This multi-node action delivers protection against cardiac ischemia, hepatic damage, and muscle wasting. The three primary members are GHRP-6, GHRP-2, and hexarelin. In GH-deficient human patients, hexarelin improved left ventricular ejection fraction (LVEF) without altering GH levels. This confirmed direct myocardial receptor action, independent of hormonal health restoration via GH.

How GHRPs work: dual-receptor mechanism and cytoprotective pathways

GHRPs bind two independent receptors with non-redundant roles. Understanding both explains why these peptides affect so many organ systems.

GHS-R1a: the growth hormone and inotropic receptor

GHS-R1a (growth hormone secretagogue receptor type 1a) is expressed in cardiomyocytes, the pituitary, and the aorta. When GHRPs bind GHS-R1a, voltage-gated calcium channels open. This triggers PKC signaling and produces a positive inotropic response (stronger heart contractions).

GHS-R1a also drives the anabolic pathway: IGF-1 production, AKT1 phosphorylation, and mTOR activation. These cascades promote muscle protein synthesis and cellular growth.

CD36: the cytoprotective and antifibrotic receptor

CD36 is a scavenger receptor expressed in monocytes, endothelial microvasculature, and cardiac tissue. Hexarelin is a confirmed CD36 ligand. CD36-null mice lose GHRP cytoprotective effects, confirming receptor specificity.

When GHRPs bind CD36, they activate the PI-3K/AKT1 pro-survival cascade. This includes HIF-1a induction and BCL2 upregulation, which inhibit apoptosis. CD36 binding also triggers PPARy upregulation, which suppresses TGF-B1 and CTGF. The result: reduced collagen deposition and extracellular matrix accumulation (antifibrotic effect).

GH independence: confirmed

Cardioprotective effects persist in hypophysectomized rats (no functional pituitary). In human GH-deficient patients, hexarelin improved LVEF without changing GH or catecholamine levels. These findings rule out GH-mediated mechanisms and confirm direct receptor action.

Convergent anti-inflammatory and antioxidant outputs

Both receptor pathways converge on two protective outputs. NF-kB suppression reduces pro-inflammatory cytokines (TNF-a, IL-6) and myeloperoxidase activity. ROS reduction preserves mitochondrial integrity during ischemic insults.

[Placeholder: Dual-Receptor Mechanism Infographic showing GHRPs → GHS-R1a (Ca2+/PKC → inotropic; IGF-1/AKT1/mTOR → anabolic) + CD36 (PI-3K/AKT1 → pro-survival; PPARy → antifibrotic)]

GHRP-6, GHRP-2 and hexarelin: named compounds compared

The three primary GHRPs share core GH-releasing and cytoprotective properties. They differ in receptor affinity, evidence base, and administration routes.

GHRP-6: the founding compound

GHRP-6 (His-DTrp-Ala-Trp-DPhe-Lys-NH2) is a hexapeptide and the most clinically studied GHRP. It is orally bioavailable, stable, and cost-effective relative to other members. A human dose-escalation trial confirmed safety via intravenous administration with no pharmacological interaction with the beta blocker metoprolol (PMC5392015).

GHRP-6 is the platform peptide for most experimental work. Merck Research Laboratories tested it in a canine dilated cardiomyopathy (DCM) and acute myocardial infarction (AMI) model in 2003. Chronic GHRP-6 pretreatment achieved 100% survival. Vehicle and GH treatment groups showed approximately 50% survival.

Hexarelin: highest cardiovascular affinity

Hexarelin shows the strongest cardiovascular binding (ventricles > atria > aorta > coronary arteries). It is a confirmed CD36 ligand. In GH-deficient patients, hexarelin improved LVEF without altering GH levels. Post-cardiac bypass surgery, hexarelin improved cardiac performance.

In a ghrelin-knockout MI model, hexarelin outperformed ghrelin: 6.7% mortality versus 14.3% for ghrelin and 50% for vehicle. This positions hexarelin as the strongest candidate for cardiac applications.

GHRP-2: antioxidant and anti-inflammatory focus

GHRP-2 protected against postischemic diastolic dysfunction in rabbit isolated perfused hearts after 14-day pretreatment. In the TO-2 hamster DCM model, GHRP-2 reduced left ventricular remodeling via antioxidant mechanisms. In LPS-challenged rats, GHRP-2 reduced circulating TNF-a, transaminases, and nitrites. It also showed antiatherogenic effects in ApoE-knockout mice.

Comparison table

Attribute	GHRP-6	GHRP-2	Hexarelin
Primary receptor	GHS-R1a + CD36	GHS-R1a	GHS-R1a + CD36 (confirmed ligand)
Routes studied	IV, oral, subcutaneous	IV, subcutaneous	IV, subcutaneous
Key cardio evidence	100% survival canine DCM/AMI; >70% myocardial salvage porcine AMI	Diastolic dysfunction protection; DCM attenuation (TO-2 hamster)	Human LVEF improvement; post-bypass cardiac performance
Key extracardiac evidence	Liver I/R protection; liver cirrhosis antifibrotic; gastric mucosa	Anti-inflammatory (LPS model); antiatherogenic (ApoE KO)	Cardiac fibrosis reduction (SHR model)
Notable safety data	Human IV dose-escalation safe; no metoprolol interaction	Preclinical safety profile	Human clinical cardiac studies
Oral bioavailability	Yes (stable, cost-effective)	Limited	Limited
2026 research status	Most studied; broadest evidence base	Growing anti-inflammatory focus	Strongest cardiac candidate

GHRPs and cardioprotection: evidence from models to human clinical data

The NIH expert panel on cardioprotection concluded that 30 years of single-target cardioprotective approaches have been largely disappointing. GHRPs’ multi-node mechanism addresses this gap directly.

Why multi-node matters

Ischemia/reperfusion (I/R) injury involves simultaneous damage from ROS overproduction, calcium overload, mitochondrial permeability transition pore (mPTP) opening, and inflammatory infiltration. Single-target drugs fail because blocking one pathway leaves others active. GHRPs hit four nodes simultaneously via their dual-receptor system.

Animal model evidence

Porcine AMI model: GHRP-6 rescued more than 70% of area-at-risk myocardium after left circumflex artery occlusion. This is among the largest salvage percentages reported for any cardioprotective agent.

Canine DCM/AMI model (Merck, 2003): Chronic GHRP-6 pretreatment (21 days) achieved 100% survival. Vehicle and GH treatment groups showed approximately 50% survival. This trial produced the most clinically compelling survival data in the GHRP literature.

TO-2 hamster DCM model: Both GHRP-6 and GHRP-2 prevented ejection fraction decline. In regression protocols, GHRP-6 achieved full LVEF recovery.

Doxorubicin-induced cardiomyopathy (rat): GHRP-6 restored LVEF in a dose-dependent manner, confirming utility against chemotherapy-induced cardiac damage.

Human clinical evidence

Hexarelin improved LVEF in GH-deficient patients without altering GH, catecholamine, or blood pressure levels. This confirmed GH-independent, receptor-mediated cardioprotection in humans.

Post-cardiac bypass surgery, hexarelin produced measurable improvements in cardiac performance. The positive inotropic effect operated through myocardial-specific GHS-R1a receptors, not through systemic hormonal changes.

[Placeholder: Cardioprotective Evidence Timeline from 1997 hexarelin ex vivo studies through 2003 Merck canine 100% survival to current 2026 research directions]

Anti-aging and anabolic effects: GHRPs for somatopause, sarcopenia and cachexia

Somatopause context

The GH/IGF-1 axis declines progressively from the 40s onward. This age-related GH decline (somatopause) produces fatigue, increased abdominal fat, reduced lean mass, and diminished recovery capacity. GHRPs stimulate endogenous pulsatile GH release rather than injecting supraphysiological exogenous GH. This preserves the body’s natural feedback loops.

Anabolic mechanisms

GHRPs promote muscle anabolism through two pathways. The first runs through GH: GHS-R1a activation triggers pituitary GH release, which stimulates hepatic IGF-1 production. IGF-1 then activates AKT1/mTOR, driving muscle protein synthesis.

The second pathway is direct. GHRP-2 exerted myoprotective effects via GHS-R1a agonism in a muscle atrophy model without elevating IGF-1. This GH-independent anabolic route may be clinically significant for patients with impaired GH/IGF-1 signaling.

Sarcopenia and cachexia data

A GHRP-6-biotin conjugate induced myogenic protein expression in preclinical models, supporting direct muscle cell activation. In a rodent cancer cachexia model, GHRP-2 increased food intake and prolonged median survival during chemotherapy. Sarcopenia affects 10 to 16% of adults worldwide and accelerates after age 60.

Athletes and recovery: what the evidence shows

GHRP-2’s direct myoprotective effect via GHS-R1a operates without requiring IGF-1 elevation. This offers a faster anabolic pathway than GH-dependent mechanisms. The GHRP-6-biotin conjugate data on myogenic protein induction also applies to recovery contexts.

For non-competitive adults, this means GHRPs may support post-exercise recovery through two channels. The GH/IGF-1 axis handles long-term tissue remodeling. The direct GHS-R1a pathway provides more immediate anti-inflammatory and muscle-protective effects.

Recovery benefits are training-dependent. GHRPs amplify the adaptive response to exercise, but they do not replace the stimulus. Without consistent resistance training, measurable recovery benefits are minimal.

WADA status: All GHRPs are classified as prohibited substances on the WADA Prohibited List. The classification falls under peptide hormones, growth factors, and related substances. They are banned in-competition and out-of-competition. Competitive athletes face sanctions for use regardless of prescription status.

Multi-organ cytoprotection: liver, kidney, lung, GI tract and CNS

The PI-3K/AKT1 and anti-inflammatory pathways activated by GHRPs operate identically across organ systems. This explains the broad cytoprotective profile.

Hepatic protection

GHRP-6 preconditioning attenuated ischemia/reperfusion liver damage in animal models, producing measurable histological and biochemical improvements. GHRP-2 reduced TNF-a, transaminases, and nitrites via liver non-parenchymal cell anti-inflammatory action in LPS-challenged rats.

Antifibrotic effects across organs

GHRP-6 reduced collagen and extracellular matrix accumulation in a liver cirrhosis model via PPARy-mediated TGF-B1 suppression. In a hypertrophic scar model, the same antifibrotic pathway reduced fibrotic tissue formation. Hexarelin reduced cardiac fibrosis in spontaneously hypertensive rats via MMP-2/MMP-9 upregulation and TIMP-1 downregulation.

Renal, pulmonary, and intestinal protection

GHRP-6 demonstrated systemic cytoprotective effects in models of acute tubular necrosis (kidney), respiratory distress-like changes (lung), and intestinal transmural infarct (GI tract). The common mechanism is PI-3K/AKT1 activation with concurrent anti-inflammatory and antioxidant activity.

Gastric mucosa

GHRP-6 prevented gastric mucosal damage via vagal efferent suppression. This has potential relevance for Curling ulcer prevention in burn and critical care patients.

Central nervous system

GHRP-6 combined with epidermal growth factor (EGF) showed synergistic neuroprotective effects in animal models of brain ischemia, multiple sclerosis, and peripheral axonal pathology. CNS applications remain early-stage.

[Placeholder: Organ-System Cytoprotection Map showing heart, liver, kidney, lung, GI tract, and CNS with GHRP evidence annotations per organ]

GHRPs vs exogenous GH and ghrelin: what makes GHRPs distinct

GHRPs vs exogenous GH replacement

Hexarelin produced superior cardiac performance improvement compared to exogenous GH after bypass surgery. GHRH (growth hormone-releasing hormone) lacks GHRP-equivalent cardioprotective activity. In hypophysectomized rats, GHRPs protected cells without any GH present, confirming that GH replacement alone cannot replicate GHRP effects.

For aging adults, this distinction matters. GHRPs stimulate endogenous pulsatile GH release, producing physiological hormone patterns. Exogenous GH injections deliver supraphysiological levels that carry higher risk of side effects (edema, joint pain, insulin resistance).

GHRPs vs ghrelin

Ghrelin is the 28-amino acid endogenous hormone that was actually discovered as a result of GHRP research. Both ghrelin and GHRPs bind GHS-R1a. In a ghrelin-knockout MI model, hexarelin achieved 6.7% mortality versus 14.3% for ghrelin and 50% for vehicle. Synthetic GHRPs may offer more reliable, dose-controllable effects than endogenous ghrelin.

Safety, regulatory status and clinical positioning in 2026

Cancer contraindication (absolute)

GH promotes cellular replication. This is beneficial in healthy tissue (muscle, bone, connective tissue) but potentially harmful when malignancy is present. GH-driven IGF-1 elevation can accelerate tumor cell proliferation and inhibit apoptosis.

GHRPs are contraindicated in patients with active cancer or a history of cancer. This is an absolute contraindication, not a relative one. The dual-receptor mechanism that makes GHRPs protective in healthy tissue (AKT1/mTOR activation, cellular growth signaling) is the same mechanism that poses risk in oncology patients.

Your prescriber should screen for cancer history before starting any GHRP protocol. If you have a personal or family history of hormone-sensitive cancers, discuss this with your provider before considering GH secretagogue therapy of any kind.

Clinical safety data

GHRP-6 is the only GHRP with published human intravenous dose-escalation safety data. The trial confirmed safety in healthy volunteers with no serious adverse events. No pharmacokinetic or pharmacodynamic interaction with metoprolol was observed. This supports feasibility for cardiovascular co-administration.

Preclinical toxicology across the GHRP family shows a broad safety margin. Common reported effects in research settings include transient flushing, increased appetite (GHS-R1a mediated), and mild water retention. Injection site reactions (redness, swelling, mild soreness) are the most frequently reported side effect in subcutaneous protocols.

Research-grade vs pharmaceutical-grade risk

“Research-grade” peptides sold through unregulated online vendors may contain impurities, incorrect doses, or contaminants. Documented risks include bacterial contamination, endotoxin exposure, and potential genotoxicity from chemical byproducts. Pharmaceutical-grade peptides from accredited 503A or 503B compounding pharmacies follow USP purity and sterility standards. Always verify your pharmacy’s state board licensing before purchasing.

FDA compounding status (2026)

GHRP-6, GHRP-2, and hexarelin are not FDA-approved drugs. Their availability through compounding pharmacies depends on current FDA 503A bulks list classification. Regulatory status follows the same Category 1 vs Category 2 framework that governs other peptide compounds. The FDA peptide reclassification proceedings may affect availability. Verify current compounding legality with your prescriber before starting any GHRP protocol.

WADA prohibited list

All GHRPs are prohibited under WADA rules. The classification falls under peptide hormones, growth factors, and related substances. This applies both in-competition and out-of-competition. Competitive athletes cannot legally use GHRPs regardless of prescription status.

Clinical development trajectory

GHRP clinical development has been erratic. Despite compelling preclinical and limited human data, no major pharmaceutical company has pursued full FDA approval. The NIH cardioprotection expert panel identified the unmet need. GHRPs’ multi-node mechanism addresses it directly. Yet clinical investment has lagged behind the science.

Several factors explain the gap. GHRPs are not patentable as new chemical entities in most jurisdictions. The commercial incentive for Phase 3 trials is low without patent exclusivity. Academic research groups continue to produce data, but funding for large human trials remains limited.

Priority research areas in 2026 include myocardial reperfusion damage, cancer-associated cachexia, and multi-organ protection in critical illness. Interest is growing in cardiology and intensive care communities. Some researchers are exploring GHRP analogs with enhanced CD36 selectivity for cardiac-specific applications.

When to consult a healthcare professional

GHRPs remain research-stage for most applications. If you are considering GHRP therapy, consult a licensed prescriber first. A qualified provider can order appropriate labs and assess contraindications. They can also source pharmaceutical-grade compounds from an accredited compounding pharmacy.

Conclusion

GHRPs deliver a uniquely broad pharmacological profile through dual-receptor binding. GHS-R1a drives GH release, positive inotropic effects, and anabolic signaling. CD36 activates PI-3K/AKT1 pro-survival, PPARy-mediated antifibrotic, and anti-inflammatory cascades. These effects are confirmed as GH-independent.

The strongest clinical evidence supports cardioprotection (>70% myocardial salvage, 100% canine survival, human LVEF improvement). Anabolic, antifibrotic, and multi-organ cytoprotective data add to the profile. GHRPs remain research-stage for most indications, and clinical development has not matched the science.

Consult a healthcare professional before use. Verify 2026 regulatory status. Prioritize pharmaceutical-grade sourcing from licensed compounding pharmacies.

Frequently asked questions

Are GHRPs on the WADA prohibited list for athletes?

Yes. GHRPs fall under the WADA prohibited list category of peptide hormones, growth factors, and related substances. They are banned in-competition and out-of-competition. Competitive athletes face sanctions for use. GHRPs should only be used under medical supervision in a non-competitive clinical context.

Can aging adults use GHRPs for somatopause symptoms?

GHRPs stimulate endogenous pulsatile GH release, which is a physiological advantage over exogenous GH injection. Clinical trials in GH-deficient patients confirm both hormonal and cardiac effects. Access requires medical supervision and a licensed prescriber. GHRPs are not available over-the-counter in the United States.

How are GHRPs different from ghrelin?

Ghrelin is a 28-amino acid endogenous hormone secreted by gastric cells. GHRPs are synthetic peptides. Both bind GHS-R1a. In a ghrelin-knockout MI model, hexarelin achieved 6.7% mortality versus 14.3% for ghrelin and 50% for vehicle. Synthetic GHRPs may offer more reliable, dose-controllable pharmacological effects.

How do GHRPs reduce inflammation?

GHRPs suppress NF-kB activation, which reduces downstream pro-inflammatory cytokines TNF-a and IL-6. In LPS-challenged rats, GHRP-2 lowered circulating transaminases and nitrites. Myeloperoxidase activity reduction has been confirmed in liver tissue and remote organs, indicating systemic anti-inflammatory action.

Can GHRPs help with fibrosis or scarring?

Preclinical evidence supports this. Via PPARy upregulation, GHRPs suppress TGF-B1 and CTGF, reducing collagen accumulation. This antifibrotic effect has been validated in liver cirrhosis, hypertrophic scar, and cardiac fibrosis models (hexarelin in spontaneously hypertensive rats). Human clinical data for antifibrotic use is not yet available.

Can people with a cancer history use GHRPs?

No. GHRPs are absolutely contraindicated in patients with active cancer or a history of cancer. GH and IGF-1 promote cellular replication, which can accelerate tumor growth. The AKT1/mTOR signaling activated by GHRPs is the same pathway that oncologists target for suppression. Discuss your full medical history with your prescriber before starting any GH secretagogue therapy.

Where is GHRP research heading in 2026?

Priority areas include myocardial reperfusion damage, cancer-associated cachexia, and multi-organ protection in critical illness settings. The NIH cardioprotection panel identified the unmet need that GHRPs’ multi-node mechanism addresses directly. Clinical development remains irregular, but interest is growing in cardiology and intensive care. Some groups are exploring CD36-selective analogs for cardiac-specific use.

How are GHRPs typically administered?

GHRPs are administered via subcutaneous injection. Dosing frequency and amount vary by compound and clinical context. A licensed prescriber determines the protocol based on baseline labs, body weight, and treatment goals. Cycling protocols (periods on followed by periods off) are common to prevent receptor desensitization. All dosing decisions require medical supervision.

This article is for informational purposes only and does not constitute medical advice. GHRPs are not FDA-approved for any therapeutic indication. Consult a licensed healthcare provider before starting any peptide therapy. Individual responses vary based on medical history, dosage, and clinical context.

peptides.io is part of the Medaly longevity discovery platform.